Aims The introduction of non-VKA oral anticoagulants (NOACs), which change from the sooner vitamin K antagonist (VKA) treatments, has changed the method of stroke prevention in atrial fibrillation (AF). Me personally. Conclusion Stage I of GLORIA-AF implies that VKAs were mainly used in sufferers with continual/long lasting (vs. Gestodene IC50 paroxysmal) AF and in people… Continue reading Aims The introduction of non-VKA oral anticoagulants (NOACs), which change from